Introduction
The recent search for a human immunodeficiency virus (HIV) vaccine has focused attention on subunit approaches to vaccine design. Knowing the possible danger of inducing antibodies which enhance infection (Robinson et al., 1989) , or mediate harmful immune responses (Golding et al., 1989) , it is conceivable that the use of peptide immunogens to induce or boost antibody responses to particular parts of the virus envelope proteins could be advantageous (Berzofsky, 1991; Wigzell, 1991) .
The use of peptides as synthetic vaccines offers several advantages (reviewed by Rowlands, 1990) , but suffers from the drawback that peptides are often poorly immunogenic. Immunogenicity can be improved by coupling to a carrier molecule or by synthesizing the peptide as part of a fusion protein. Particularly successful examples of the latter approach have involved the use of proteins which can self-assemble into polymeric particulate structures. These include hepatitis B core (Clarke et al., 1987) and surface (Valenzuela et al., 1985) antigens, capsid proteins from poliovirus (Burke et al., 1988) and Ty protein from yeast (Adams et al., 1987) .
Properties of hepatitis B core antigen (HBcAg) which make it suitable for the purpose described above include the ability of the 21K monomer to self-assemble into 27 nm particles when expressed in a variety of prokaryotic and eukaryotic systems (Pasek et al., 1979; Kniskern et al., 1986; Lanford et al., 1989; Clarke et al., 1987 ). The core fusion particle (CFP) is a versatile carrier: particles have been described in which peptides were inserted at one of three different sites in the molecule, either as N-terminal fusions (Clarke et al., 1987) , truncated C-terminal fusions (Stahl & Murray, 1989) or within an internal immunodominant region (Schodel et al., 1992; Brown et al., 1991) . Presentation of specific epitopes from other viral agents, for example human rhinovirus (Clarke et al., 1990 ) and foot-and-mouth disease virus (Clarke et al., 1987; F. Brown & B. E. Clarke, unpublished results) on CFPs have resulted in subunit vaccines capable of inducing high titres of virusneutralizing antibodies. A further relevant property of CFPs is their ability to induce T cell-independent antibody responses (Milich & McLachlan, 1986) , a property which has significant implications for postexposure therapeutic treatment of HIV and its associated opportunistic infections. Previously , we have described the synthesis of CFPs carrying an epitope from the envelope protein of HIV-1 (amino acids 735 to 752) which can induce virus-neutralizing antibodies in small animals (Chanh et al., 1986) .
Simian immunodeficiency virus (SIV) infection of macaques is a widely used model system for HIV infection of humans which allows vaccine challenge experiments to be performed. Accordingly, as a first step in evaluating the use of CFPs in HIV vaccine strategies, particles containing SIV peptides were made and the immune responses of small animals to these particles were examined. Peptides were inserted at the N or C terminus of the core molecule or within an internal immunodominant site . As little is known about which peptides from SIV can induce antiviral responses, peptides were chosen mostly from variable regions of the envelope proteins or regions with homology to HIV neutralization epitopes. We found that the N-terminal and internal presentation of the SIV peptides induced good antipeptide antibody responses, but that the C-terminal fusions were not immunogenic. Conventional antipeptide antisera were also made in parallel to keyhole limpet haemocyanin (KLH) conjugates but we were unable to detect virus-neutralizing activity in either the anti-CFP or anti-KLH conjugate sera.
Methods
Construction of expression vectors. Unless otherwise stated, all recombinant DNA work and protein expression was performed in Escherichia coil strain XLl-blue. The vector pPV-Nhe which expresses HBcAg internal el loop fusions in E. coil under the control of the tac promoter was described previously . This vector was modified initially by polymerase chain reaction (PCR)-based sitedirected mutagenesis to remove the poliovirus epitope and to introduce a novel restriction site (SpeI) near the 5' end of the gene (QI0, QI 1, Fig.  1 ). These vectors were modified further by mutation of a natural XbaI site within the gene and reintroduction of the same site at the 3' end of the coding sequence (Q15, Fig. 1 ). The presence of the unique SpeI, NheI and XbaI sites allows insertion of the same heterologous epitope into different parts of the molecule using the same oligonucleotide linkers. Details of the exact DNA manipulations are available on request.
Expression of fusion proteins. Regions coding for peptides to be expressed as CFPs were synthesized as PCR fragments designed with terminal NheI sites which allow insertion into the NheI, SpeI and XbaI sites of the vectors. All SIV envelope-coding sequences were taken from the SIVmac32H(pJ5 ) molecular clone (Rud et al., 1992) and all DNA insertions were checked by sequence analysis. Fusion proteins were expressed in E. coil and particles purified as described previously .
Peptides. Peptides were synthesized as described by Houghten (1985) . The peptides synthesized in this study (Table 1) included those introduced into HBcAg, except that the SIV V1 peptide was shorter (SLTTTAPTAPTAASKIDC). All peptides had an additional cysteine residue at their C termini to facilitate coupling to KLH (Liu et al., 1979) .
Animal immunizations and sera. Groups of female Dunkin Hartley guinea-pigs (Harlan Porcellus) were used for immunogenicity studies. For CFP immunizations, groups of four animals were immunized on day 0 and day 70 with preparations formulated in incomplete Freund's adjuvant (IFA), and samples were collected on day 98. For the N-terminal fusions an additional boost was given on day 98 and samples were collected on day 126. Antigen doses were calculated so that each animal received approximately 20 ~tg of the SIV CFP per dose (corresponding to 2 Ixg of the peptide sequence).
Antipeptide sera were raised by immunizing pairs of animals with peptide coupled to KLH in complete Freund's adjuvant (CFA). Each animal received 100 ~tg peptide per dose and was boosted with the same amount of peptide in IFA on days 70 and 98. Samples were collected on day 126.
ELISA and Western blots. Antipeptide activities in serum samples were measured using the indirect ELISA method (Voller et al., 1976) . Peptides were dried onto the plate overnight at 37 °C and then fixed with methanol. The plates were washed and incubated with test samples at a range of 0.5 loglo dilutions in PBS/2% dried milk powder. Following incubation for 1 to 2 h at 37 °C, plates were rewashed and anti-guinea-pig peroxidase conjugate (Dako, 1000-fold dilution) was added. After a further 1 h incubation at 37 °C, the plates were washed and developed with an enzyme substrate as previously described . Reactivity of the mouse anti-SIV V2 monoclonal antibody (MAb) KK13 (Kent et al., 1991 (Kent et al., , 1992 with V2 peptides expressed in CFPs was assayed by a modified double-antibody sandwich ELISA (Voller et al., 1976) . Guinea-pig polyclonal antiHBcAg serum (100-fold dilution) was used to capture serial dilutions (starting from 100 Ixg/ml) of CFPs in PBS/2% dried milk powder. The plates were incubated for 16 h at 4 °C, washed, incubated with the mouse MAb KK13 for 2 h at 37 °C, rewashed and further incubated with a rabbit anti-mouse IgG-peroxidase conjugate (Dako).
Absorbance values (at 492 nm; A492) obtained from post-inoculation sera were plotted against the log~o reciprocal antiserum dilution and the antibody titre was calculated by reference to a negative standard (10-fold dilution of preinoculation serum).
For Western blotting analysis (Towbin et al., 1979) , proteins were fractionated on 12.5% SDS-polyacrylamidc gels, transferred to nitrocellulose and analysed by reaction with guinea-pig or murine sera. Following incubation with anti-species peroxidase conjugates the antibody staining was visualized with diaminobenzidine hydrochloride (Sigma) and hydrogen peroxide.
Virus neutralization assays. SIV neutralization assays were modified from those previously described (Kent et al., 1991) and were quantified by measuring the inhibition of SIV p24 antigen (T. Corcoran, unpublished results).
Results

Construction of vectors for expression of peptides as N-and C-terminal fusion proteins with HBcAg
The vector pPV-Nhe allows expression of a core protein carrying a poliovirus epitope at its N terminus. The plasmid also contains a restriction site (NheI) which was inserted in the core gene within a region coding for an immunodominant epitope, allowing the introduction of foreign peptides between amino acids 80 and 81 of the core protein. To facilitate further manipulation of the coding sequence two new vectors were produced, Q10 and Qll (Fig. 1) , which allow insertion of coding sequences bearing the cohesive ends generated by SpeI, XbaI, NheI or AvrII in either the N-terminal coding region (SpeI) or the internal site (NheI) of the HBcAg gene (Fig. 1) . Expression from Q10 and Qll is driven by the lac or tac promoters respectively.
To produce a vector capable of receiving inserts at all three sites in HBcAg which have been described, the TsCT CGAR GAAE TCTs AGAR TGTc TAG, ]j . Guinea-pig antibody titres to the CFPs. Groups of four guineapigs were immunized and samples were taken as described in Methods. Sera from each group were pooled, and antipeptide antibody titres were measured by ELISA. Titres are expressed as loglo reciprocal antibody dilution.
XbaI site of Q10 was deleted and reintroduced at the extreme C-terminal end of the gene to give the vector Q15 (Fig. 1) . This vector expresses CFPs from the lac promoter and accepts the same D N A inserts as Q I 0 and Q11. The C-terminal site at which insertions are made is not the same as that used by other groups. We have inserted at amino acid 183 of the core protein, whereas previous fusions were made at amino acids 144 (Stahl & Murray, 1989) and 156 (Schodel et al., 1992) and resulted in deletion of the arginine-rich region at the C terminus of the protein. This difference may be important since our C-terminal fusions did not induce significant antipeptide responses (see below) although the anti-core responses were unaffected.
S I V fusion particles
When this study was initiated the only description of peptides from SIV proteins which appeared to induce protective responses in macaques was a mixture of four #-galactosidase-peptide fusion proteins (Shafferman et al., 1991) . One of these peptides ($4, Table 1 ) was inserted into core particles. This peptide was chosen because antipeptide responses to it correlated best with protection in the Shafferman experiments. Two of the chosen SIV peptides originated from the first and second hypervariable regions of the envelope (V1 and V2, Table 1 ). It was reasoned that if this variation represented escape from immune pressure, these regions might be important for induction of virusneutralizing responses. The other three SIV peptides inserted into HBcAg were chosen as homologues to regions of the HIV-1 envelope that were either immunodominant or capable of inducing virus-neutralizing antibodies. Peptide V3 is from the region homologous to the principal neutralizing domain of H I V gp 120 (Goudsmit et al., 1988) , peptide G is from the region homologous to the immunodominant domain of H I V gp41 (Gnann et al., 1987) and peptide K is homologous to a neutralizing epitope of H I V gp41 (HK) (Chanh et al., 1986) . All SIV peptide sequences were taken from the molecular clone SIVmac32H(pJ5) (Rud et al., 1992) and were expressed in vectors Q11 and Q15.
Immunogenicity of particles
Groups of guinea-pigs were immunized with core preparations, boosted and serum samples were taken at 28 days post-boost. Sera from each group were pooled and assayed for reactivity against the corresponding peptide (Fig. 2) . As expected, the N-terminal and internal fusions gave good antibody titres, the internal fusion responses being about an order of magnitude higher. Surprisingly, the C-terminal fusion proteins did not induce any detectable antipeptide response.
To determine whether the observed failure of these C-terminal CFPs to stimulate an antipeptide response was simply due to the peptide being hidden within the particle, a capture ELISA was performed. CFPs bearing the SIV V2 peptide at the N terminus (immunogenic) or at the C terminus (non-immunogenic) were trapped with an anti-core serum and the surface exposure of the peptide on the particles was measured using the anti-V2 M A b KK13 (Kent et al., 1991 (Kent et al., , 1992 . The second antibody reacted strongly with the trapped N-terminal fusion but very weakly with the C-terminal fusion (Fig.  3) . The simplest explanation for this is that the extra core sequences retained in our C-terminal fusions cause the foreign peptide to be presented away from the surface of the particle. However this observation could also be accounted for if the peptide were presented in a conformation that the MAb could not recognize.
Reaction of sera with S I V env proteins, and neutralization assays
Each of the sera was tested for its ability to recognize viral envelope proteins. SIV-specific antisera were analysed by Western blotting with vaccinia virusexpressed SIV envelope proteins (Fig. 4) . The envelope protein expressed was the precursor gpl60 from the homologous SIVmae32H(pJ5) gpl60 which contains sequences identical to those in the CFPs (E. W. Rud & M. Mackett, unpublished results). All of the anti-fusion particle sera reacted with the envelope protein (gpl60), although there was no correlation between the reaction in Western blot (as judged by the speed of colour development) and ELISA antipeptide titre. In fact the highest titred serum, raised to the V1 CFP, gave the weakest reaction in the Western blot. Also included in Fig. 4 are the results obtained with antipeptide sera raised to KLH-conjugated SIV env peptides. These sera had high antipeptide titres (Table 2) and, again, the sera raised to peptides V1, V2, $4 and K reacted with envelope protein. Sera raised to peptide S1 also reacted but, surprisingly, sera raised to peptides V3, V3-2, C-term and G failed to react with the envelope protein in Western blots. Interestingly, several of the peptides elicited immune responses in guinea-pigs when not coupled to carrier proteins, indicating the presence of functional T helper cell signals within the sequence. 
CFPs Peptides r~
The anti-CFP and antipeptide sera were tested in vitro for virus neutralization activity (Table 2) . None of the sera generated in this study had detectable neutralizing activity although the V2 region of SIV gpl20 has been reported to be a neutralizing site (Kent et al., 1992) . It may be that antibodies which bind to this region and neutralize the virus recognize a particular conformation of this peptide and that neither the CFP-nor the KLHconjugated peptide was able to induce antibodies of the required specificity. In this respect it is important to note that it has been observed that some anti-V2 MAbs also do not neutralize SIV infection (Kent et al., 1992) . Fig. 4 . Western blot analysis of sera derived from fusion particle or peptide immunizations. Anti-SIV-specific sera were analysed against gpl60 from the molecular clone S1Vmac32H(pJ5) when expressed in HuTK-143B cells by infection with a vaccinia virus recombinant v9002 (E. W. Rud & M. Mackett, unpublished results). Total infected cell proteins were fractionated on 12-5~ SDS-polyacrylamide gels, transferred to nitrocellulose and reacted with guinea-pig anti-CFP or anti-peptide-KLH sera as indicated. All SIV peptide sequences were derived from the molecular clone SIVma¢32H(pJS).
Table 2. Antipeptide and neutralization titres of anti-CFP and antipeptide sera
Antipeptide Western Immunogen titre (log10) blot (env) Neutralization V I C F P e l loop 4.9 + -V 2 C F P N -t e r m 3.8 + + -$ 4 C F P N -t e r m 3-3 ND* --$ 4 C F P e l loop 4.4 + + -K C F P e l loop 4.0 
Discussion
SIV infection of macaques is a widely used animal model for HIV infection in humans (Gardner, 1991; Miller & Gardner, 1991) . CFPs are a possible presentation system for SIV peptides for use in vaccine development studies in this animal model. Our choice of SIV peptides was largely predictive: of those chosen only the V2 peptide has been shown to come from a neutralizing site, the others being picked for homology to HIV-1 neutralizing sites or because they represented hypervariable regions of the envelope. The core fusions carrying insertions at the N terminus and internal fusions both induced good antipeptide antibody responses, whereas those carrying C-terminal peptides did not induce detectable antipeptide antibody titres. This contrasts with results previously described with C-terminal fusions (Stahl & Murray, 1989) , where the fusions were found to be immunogenic, and those presented in a more recent report (Schodel et al., 1992) where C-terminal fusions were found to be exposed on the surface of the particles and weakly immunogenic. There are two main differences between our experiments and those described earlier. First, all our CFP preparations were formulated in IFA whereas earlier studies used the much more potent adjuvant CFA. Second, we inserted peptides at the extreme C terminus of the core molecule whereas in the other reports the arginine-rich region at the C terminus of the core molecule was deleted in making fusions. This region is thought to interact with encapsidated nucleic acid in the hepatitis B virion (Matsuda et aL, 1988) . The presence of this sequence may be responsible for the lack of immunogenicity of our Cterminal fusions by ensuring that the peptides are on the inside of the particle.
Some of the sera raised in this study failed to react with the envelope glycoprotein from which the peptide sequences were taken (Fig. 4) . These sera (raised to KLH-conjugated peptides V3, CD and CT) did not have low antipeptide titres, suggesting that the conformations of these peptides as KLH conjugates is different from their conformations when part of a larger protein.
None of our polyclonal sera directed against CFP or peptide-KLH conjugates had detectable neutralization activity. Since MAbs that react with the V2 sequence used here have virus-neutralizing activity in this assay (Kent et al., 1992) , the lack of neutralization induced by V2 CFP, free peptide or peptide-KLH conjugate is puzzling. However not all of the MAbs that bind to this peptide have neutralizing activity (Kent et al., 1992) . Also, the neutralizing MAbs have far higher antipeptide titres than virus neutralization titres, so it is possible that our sera did not have sufficiently high titres. It is also possible that the neutralizing MAbs recognize the peptide in a particular conformation, and that the free peptide, peptide-KLH conjugate and CFP are not able to mimic this conformation and so cannot induce neutralizing antibodies. To address this possibility, we are now attempting to present the V2 peptide in the internal site of HBcAg, as peptides presented in this site are conformationally restricted and may resemble more closely the peptide conformation in the virus. However, it is worth noting that a neutralizing MAb reacts with both the V2 peptide and CFP (K. Kent, unpublished results) .
One of the peptides described by Shafferman et al. (1991; peptide $4) was included in a CFP but did not induce neutralizing antibodies. We took the other peptide sequences used in that study and injected them as KLH conjugates and again failed to induce neutralizing antibodies in guinea-pigs (peptides S1, C-term and G in Table 2 ). Since Shafferman et al. (1991) induced neutralizing antibodies in macaques with a mixture of these four peptides presented as fl-galactosidase fusion proteins, the lack of neutralization in our experiments may reflect either a species difference or the requirement for several of the peptides in the inoculum to generate a neutralizing response. Furthermore, Shafferman et al. (1991) showed that the macaques became infected but appeared to gain protection against disease; therefore it is possible that the protective effect was mediated by some mechanism other than induction of virus-neutralizing antibody.
Recently, Bjorling et al. (1991) described several peptides from the envelope proteins of HIV-2 which were able to induce virus-neutralizing antibodies in guinea-pigs. Four of their peptides were derived from regions corresponding to those which we used (peptides V1, V3 and V3-2, C-term and K). However we did not detect neutralization with any of these peptides.
Despite the lack of neutralization activity in the sera, presentation in HBcAg is a useful method for inducing high titre antibodies against particular SIV peptides. It is not yet clear that generation of neutralizing antibodies is the only method by which protection against SIV (or HIV) or against virus-induced disease can be achieved. Possibly antibodies induced to certain SIV peptides can mediate protective responses by mechanisms other than virus neutralization (for example by antibody-dependent cell-mediated cytotoxicity), and presentation systems such as CFPs may prove useful for inducing these responses.
The system also offers the possibility of generating T cell-independent responses to presented peptides, which may be important in T cell-depleted individuals. Experiments to measure T cell-independent responses to some of the CFPs described here are in progress.
